VLN Biotechnology Hires Dr. Paul O’Reilly from the University of Ottawa
VLN Biotechnology - a Company focused on development of immunotherapy against the common allergenic molds Alternaria & Cladosporium
Said Dr. Hari Vijay, Chief Scientific Officer, “I’m delighted that Paul has joined the VLNB team. His strong background in cDNA cloning and antibody technologies will accelerate our development of novel mold immunotherapies”
The American College of Occupational and Environmental Medicine (http://www.acoem.org/)
VLNB seeks to partner with companies and research organizations to accelerate commercial development of immunotherapy to treat mold allergies. VLNB also offers customized consulting services led by Dr. Hari Vijay.
About VLN Biotechnology
VLN Biotechnology is commercializing immunotherapy technology to improve the health and quality of life of patients suffering from allergies to mold. We are focused on improved detection of allergenic proteins responsible for allergic reactions and development of immunotherapy to alleviate symptoms of mold allergies. VLN Biotechnology was founded by Dr. Hari Vijay, an acknowledged global expert on mold allergens. For further information please visit www.vln-biotech.com.
VLN Biotechnology Inc.
5303 Canotek Road
Ottawa, ON K1J 9M2